Spanish Researchers Treated Breast Cancer With Cannabinoids
In 2010, a team of Spanish researchers published a study in the journal Molecular Cancer with the intent to “determine whether cannabinoids might constitute a new therapeutic tool” in the treatment of HER2-positive breast cancer. They analyzed the anti-tumor potential of tetrahydrocannabinol (THC) and a synthetic cannabinoid with similar effects to cannabidiol (CBD).
In order to analyze each cannabinoid’s potential, the researchers investigated their effects on mice with a similar form of cancer – the Mouse Mammary Tumor Virus. In addition to mouse trials, the researchers examined the effects of cannabis on 87 human breast tumors.
“Cannabinoids may inhibit [cancerous] cell proliferation and induce programmed cell death.”
According to the study’s results, THC and CBD had a number of anti-cancer benefits in mice. Both cannabinoids investigated were found to inhibit cancer growth, reduce the number of tumors, and reduce the number and/or severity of metastases (secondary tumors in the lungs).
In studying the human cancer tissue, the researchers found that cannabinoids may inhibit cell proliferation and induce programmed cell death, or aptosis. According to the study, cannabinoids also seem to “impair tumor angiogenesis,” which allows tumors to receive more nutrients by causing blood vessels to grow.
One of the most pertinent findings, according to the study, is that 91% of HER2-positive tumors actively express CB2 receptors. As we know, both THC and CBD interact with CB2 receptors, and this could explain their interaction with breast cancer.